KEGG   DRUG: BasiliximabHelp
Entry
D03058                      Drug                                   

Name
Basiliximab (USAN/INN);
Basiliximab (genetical recombination) (JAN);
Simulect (TN)
Product
Class
Other
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 6399
ATC code: L04AC02
Product: D03058<JP/US>
Efficacy
Immunosuppressant, Anti-CD25 antibody
  Disease
Prophylaxis of acute organ rejection [DS:H00083]
Comment
Monoclonal antibody
Target
IL2RA (CD25) [HSA:3559] [KO:K05068]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04144  Endocytosis
hsa04630  JAK-STAT signaling pathway
hsa04640  Hematopoietic cell lineage
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC02 Basiliximab
      D03058  Basiliximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunomodulators
   Basiliximab
    D03058  Basiliximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D03058  Basiliximab (USAN/INN); Basiliximab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RA (CD25)
     D03058  Basiliximab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03058
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03058
BRITE hierarchy
Other DBs
CAS: 179045-86-4
PubChem: 17397213
DrugBank: DB00074
NIKKAJI: J1.892.794B
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system